<DOC>
	<DOCNO>NCT00006220</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Tretinoin may help hematologic cancer cell develop normal white blood cell . PURPOSE : Phase I/II trial study effectiveness arsenic trioxide without tretinoin treat patient hematologic cancer respond previous therapy .</brief_summary>
	<brief_title>Arsenic Trioxide With Without Tretinoin Treating Patients With Hematologic Cancer That Has Not Responded Previous Therapy</brief_title>
	<detailed_description>This dose escalation efficacy study arsenic trioxide . In efficacy study , patient stratify accord diagnosis ( acute myelogenous leukemia v acute lymphocytic leukemia v myelodysplastic syndrome v multiple myeloma v non-Hodgkin 's lymphoma Hodgkin 's disease ) . Phase I : Patients receive arsenic trioxide IV 2 hour daily 28 day . Treatment repeat every 42-59 day absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) partial remission ( PR ) receive 4 course . Patients fail achieve CR PR experience disease progression may receive arsenic trioxide tretinoin daily 28 day every 42-59 day 7 course . Patients fail achieve CR PR experience disease progression arsenic trioxide tretinoin remove study . Cohorts 3-6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Phase II : Patients receive MTD arsenic trioxide phase I 7 course . Patients fail achieve CR PR 3 course experience disease progression either take study treat arsenic trioxide tretinoin phase I . Patients follow monthly 6 month , every 3 month 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients follow diagnosis : Acute lymphocytic leukemia OR acute myeloid leukemia Failed achieve complete remission ( CR ) induction chemotherapy OR Relapsed within one year initial CR OR Relapsed autologous allogeneic transplant OR Any subsequent relapse OR Refractory follow relapse CR2 ( phase I ) Blastic phase chronic myelogenous leukemia Prior therapy allow Myelodysplastic syndrome , include follow : Refractory anemia excess blast ( RAEB ) OR RAEB transformation ( high intermediate high risk ) Relapsed transplant CR2 ( phase I ) NonHodgkin 's lymphoma OR Hodgkin 's disease Newly diagnose first relapse fail achieve CR partial remission induction salvage chemotherapy OR Second later relapse OR Relapsed transplant No disease encompass standard radiation port No asymptomatic , minimally symptomatic , low grade lymphoma Multiple myeloma Symptomatic , progressive , recurrent disease treatment alkylating agent , high dose corticosteroid , anthracyclines OR Relapsed follow transplant Not eligible autologous allogeneic transplant A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 500/mm3* Platelet count least 50,000/mm3* *Unless cause marrow infiltration tumor No congenital bleed disorder Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 3 time ULN Renal : Creatinine clearance great 25 mL/min Cardiovascular : No myocardial infarction , stroke , unstable angina within past 12 month No uncompensated congestive heart failure Left ventricular ejection fraction least 40 % Other : No active infection HIV negative HTLV I/II negative Not pregnant Fertile patient must use effective contraception 2 year follow study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Prior hydroxyurea allow Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : Not specify Other : At least 3 week since prior antileukemic therapy ( except leukapheresis )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>